



GRU 1634

PATENT

Docket No. 2026-4116US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Bukh, et al. Group Art Unit : 1634  
Serial No. : 09/084,691 Examiner : Sisson, B.  
Filed : May 26, 1998  
For : NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF THE  
ENVELOPE 1 AND CORE GENES OF ISOLATES OF HEPATITIS C  
VIRUS AND THE USE OF REAGENTS DERIVED FROM THESE  
SEQUENCES IN DIAGNOSTIC METHODS AND VACCINES

CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Sir:

I hereby certify that the attached 1) Response to Restriction Requirement; and 2) Return postcard

(along with any paper(s) referred to as being attached or enclosed) and this Certificate of Mailing are being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Dated: September 28, 1998

By: Richard W. Bork  
Richard W. Bork  
Registration No. 36,459

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN LLP  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800  
(212) 751-6849 Facsimile  
FORM: CERT..NY  
Rev. 05/27/98

RECEIVED  
TECH CENTER 1600/2900  
98 OCT -6 PM 2:44



# 3  
Election 10/17/98  
**PATENT**  
Docket No. 2026-4116US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Bukh, et al. ✓ Group Art Unit: 1634 ✓  
Serial No. : 09/084,691 ✓ Examiner : Sisson, B. ✓  
Filed : May 26, 1998 ✓  
For : NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF THE  
ENVELOPE 1 AND CORE GENES OF ISOLATES OF HEPATITIS C  
VIRUS AND THE USE OF REAGENTS DERIVED FROM THESE  
SEQUENCES IN DIAGNOSTIC METHODS AND VACCINES ✓

Assistant Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

RECEIVED  
TECH CENTER 1600/2900  
98 OCT -6 PM 2:44

In a restriction requirement dated August 28, 1998, the Examiner has restricted

the claims of the invention into the following groups:

- I. Claims 1 and 3, drawn to DNA;
- II. Claims 2 and 4-5, drawn to protein and claims 32 and 38, drawn to HCV genotype-specific peptides; claims 6-8, drawn to a recombinant method of synthesizing said proteins and recombinant method of making same; claims 9, 17, 47, and 48, drawn to expression vector; and claim 10, drawn to host cell;
- III. Claims 11-14, 33-36, 39-42, and 59, drawn to a method of detecting anti-HCV antibodies, and claims 15 and 37, drawn to a related kit;
- IV. Claims 18, 45, and 49, drawn to method of preventing hepatitis C infection, and claims 16, 19, 20, 43, 44, 46, 50, 51, drawn to a vaccine;

- V. Claims 52-54, drawn to antibodies; and
- VI. Claims 55-58, drawn to an immuno-based method of detecting core proteins specific for a single genotype of HCV.

In reply, Applicants respectfully elect, with traverse, the claims of group II, claims 2, 4-10, 17, 32, 38, 47 and 48.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: September 28, 1998

By: Richard W. Bork  
Richard W. Bork  
Reg. No. 36,459

MAILING ADDRESS:

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800  
(212) 751-6849 (FAX)